Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer

 

> Read the media release

Identifying ALK+ NSCLC patients for targeted treatment

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients

 

> Read the media release

Guiding immunotherapy for non-small cell lung cancer

VENTANA PD-L1 (SP263) Assay label expanded to identify NSCLC patients eligible for treatment with KEYTRUDA® (pembrolizumab) in countries accepting the CE mark

[CE mark only, not FDA approved]

 

> Read the news release

Featured Stories



Tissue Expressions

Case Studies

Tucson Symposium